Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-hmC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations

Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review

(2018) Rossella Bruno et al.   Journal of Thoracic Disease

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

(2017) Tomoyuki Hida et al.   LUNG CANCER

New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?

(2016) Andrew Churg et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

BAP1 Immunostain andCDKN2A(p16) FISH Analysis

(2016) Ann E. Walts et al.   DIAGNOSTIC CYTOPATHOLOGY

Role of TET enzymes in DNA methylation, development, and cancer

(2016) Kasper Dindler Rasmussen et al.   GENES & DEVELOPMENT

Loss of expression of BAP1 is very rare in non-small cell lung carcinoma

(2016) Juliana Andrici et al.   PATHOLOGY

BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests

(2016) Tomoyuki Hida et al.   PATHOLOGY INTERNATIONAL

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

(2016) Michele Carbone et al.   Oncotarget

Characterization of preneoplastic and neoplastic rat mesothelial cell lines: the involvement of TETs, DNMTs, and 5-hydroxymethylcytosine

(2016) David Roulois et al.   Oncotarget

BAP1 Immunohistochemistry and p16 FISH to Separate Benign From Malignant Mesothelial Proliferations

(2015) Brandon S. Sheffield et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma

(2015) Stephanie M. McGregor et al.   HUMAN PATHOLOGY

High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma

(2015) Masaki Nasu et al.   Journal of Thoracic Oncology

5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy

(2015) Aparna Vasanthakumar et al.   Cancer Genetics

Tissue-Specific Differences in DNA Modifications (5-Hydroxymethylcytosine, 5-Formylcytosine, 5-Carboxylcytosine and 5-Hydroxymethyluracil) and Their Interrelationships

(2015) Daniel Gackowski et al.   PLoS One

The role of mutation of metabolism-related genes in genomic hypermethylation

(2014) Joshua J. Waterfall et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

5-Hydroxymethylcytosine is a predominantly stable DNA modification

(2014) Martin Bachman et al.   Nature Chemistry

Comparative Immunohistochemical Analysis of IMP3, GLUT1, EMA, CD146, and Desmin for Distinguishing Malignant Mesothelioma From Reactive Mesothelial Cells

(2013) Hiroshi Minato et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Distinguishing benign from malignant mesothelial cells in effusions by Glut-1, EMA, and Desmin expression: An evidence-based approach

(2011) Michael Kuperman et al.   DIAGNOSTIC CYTOPATHOLOGY